Chengda Pharmaceutical (301201) Strong Performance Analysis: Transformation-Driven Growth and Capital Game

Chengda Pharmaceutical (301201), a GEM-listed pharmaceutical CDMO company, recently entered the strong stock pool. On November 18, it rose by 20.01% in a single day with a turnover of 1.45 billion yuan and a turnover rate of 23.07%, and its stock price hit a 60-day high [0][5]. The company’s business covers pharmaceutical intermediates, custom R&D of APIs, and the cell and gene therapy field [0].

• Business Transformation Drive
  : The company is transforming to cell and gene therapy CDMO, and institutions like Caitong Securities have released research reports optimistic about its development prospects [0][4].
• Active Participation by Hot Money
  : Dragon and Tiger List data shows that well-known hot money players like Zhang Mengzhu and Zuoshou Xinyi are on the list, with extremely high market attention [1][3].
• Favorable Sector Policies
  : The company has been included in the cellular immunotherapy sector and benefited from industry policy support [0].

• Technical Aspect
  : The stock price broke through the 60-day high, with obvious net inflow of main funds [2][5].
• Fundamental Aspect
  : The CDMO business layout is complete, and expansion into the cell and gene therapy field provides support for long-term growth [0].

• Main Risks
  : Institutional capital net outflow was 10.521 million yuan, indicating market divergence [6]; the large short-term increase may face correction pressure [0].
• Opportunity Window
  : The industry has great growth potential, and the activity of hot money provides momentum for short-term market trends [0].
• Sustainability
  : It is necessary to observe the follow-up trends of hot money, institutional attitudes, and transformation progress [0].

Chengda Pharmaceutical’s recent strong performance comes from business transformation expectations and hot money-driven momentum, but institutional capital outflow warrants caution. Investors should view short-term fluctuations rationally and pay attention to the company’s transformation progress and changes in industry policies.